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Background. While the eﬃcacy of cognitive stimulation (CS) has been demonstrated in patients with dementia, no study has
included patients with Parkinson’s disease dementia (PDD). Objective. For the ﬁrst time, this randomized crossover pilot
study examined the feasibility and potential eﬀects of CS in PDD. Methods. All residents of a PDD-speciﬁc long-term care
unit in the Netherlands that were eligible for the study (n � 12) were randomly allocated to group A (n � 6) receiving CS
(eight weeks, twice weekly for 60minutes) or group B (n � 6) receiving usual care (control group, CG). *e CG participated
in CS afterwards, resulting in an experimental group (EG), consisting of n � 12. Pre- and postassessments and a six-week
follow-up (FU) were conducted for cognition, neuropsychiatric symptoms, quality of life (QoL), and activities of daily living
(ADL) outcomes. Results. Between-group analysis with diﬀerence scores from pre- to posttest revealed a group diﬀerence for
global cognition (CERAD total score) favoring the EG, with a moderate eﬀect size and a p value just failing to reach statistical
signiﬁcance (p � 0.067; r � 0.43). A further statistical trend was observed for neuropsychiatric symptoms, again with
a moderate eﬀect size (p � 0.075; r � 0.42). Within-group analyses indicated improvement only in the EG with large eﬀects
also just failing to reach signiﬁcance for global cognition (short term, p � 0.060; r � 0.70) as well as for depression (long term,
p � 0.072; r � 0.61). ADL deteriorated signiﬁcantly at FU in the EG (p � 0.014; r � 0.71). Conclusions. Although our data are
preliminary due to the small sample size, this study shows that CS is feasible and potentially eﬀective for cognitive and
noncognitive outcomes in PDD patients. Randomized controlled trials with larger sample sizes are needed to conﬁrm these
promising results.
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1. Introduction
Parkinson’s disease dementia (PDD) is highly prevalent [1]
and impacts patients, caregivers, and the health-care system
[2]. Currently, there are limited pharmacological treatments
available for PDD [3, 4]. *us, nonpharmacological in-
terventions to treat or prevent cognitive symptoms are in-
creasingly identiﬁed as promising therapy options in
Parkinson’s disease (PD) [5, 6].
Meta-analyses of controlled and randomized controlled
trials (RCTs) have shown the eﬃcacy of cognitive training on
cognitive and noncognitive symptoms in nondemented PD
patients [5, 7]. Similarly, one pilot study on goal-oriented
cognitive rehabilitation in PDD patients revealed beneﬁts in,
e.g., self-rated goal attainment, mood, and quality of life
(QoL) [8]. Surprisingly, while cognitive stimulation (CS)
(i.e., cognitively stimulating activities in small groups tar-
geting the stabilization or improvement of global cognitive
and social functioning primarily in patients with dementia
[9, 10]) has been demonstrated to be eﬀective in non-PD
dementia patients [10–12], to the best knowledge of the
authors, no study has examined its eﬀects in PDD patients
(although a study protocol has been recently published [13]).
*us, we conducted a pilot randomized crossover trial of
CS in PDD patients to examine the feasibility and potential
eﬀects. We hypothesized that CS is feasible in this context
and that the PDD patients participating in a CS program
would show beneﬁts in cognition, neuropsychiatric symp-
toms, and QoL.
2. Materials and Methods
*e reporting of this pilot RCT follows the CONSORT
guidelines [14]. *e study was registered in the German
Clinical Trials Register (DRKS; ID: DRKS00011776) and was
approved by the Ethics Committee of Lu¨ckerheide initiated
by the MeanderGroep, Kerkrade, the Netherlands. Research
was conducted in accordance with the 1975 Declaration of
Helsinki. Before starting with data assessment, legal rep-
resentatives gave informed written consent. No published
study protocol exists.
2.1. Setting and Participants. *e data assessment occurred
between January 2017 and June 2017 in a long-term care
facility in Kerkrade, the Netherlands.*is institution is unique
as, to the best knowledge of the authors, it is the only facility
with a speciﬁc care unit for residents with PD and cognitive
dysfunctions. At the beginning of the study, 21 PD patients
lived in the unit. *e aim was to include as many patients as
possible from the care unit. *erefore, the inclusion criteria
were deﬁned rather broadly as (i) being a resident in the PD
care unit, (ii) idiopathic PD diagnosed by a neurologist or
psychiatrist, (iii) cognitive dysfunction operationalized by the
Mini-Mental State Examination (MMSE; 10 to 25 points) [15],
(iv) Dutch as the native language or very good Dutch language
skills, (v) only slightly restricted or corrected-to-normal vision
and hearing, and (vi) the provision of written consent from
a legal representative to participate in the study.
*e exclusion criteria were (i) depressive symptoms,
which were not compatible with the participation in a CS
program, (ii) bedridden residents, as this is an obstacle for
participating in the group intervention, (iii) life-threatening
illness, (iv) history of alcohol or drug abuse in the last three
years, and (v) acute suicidal tendencies or acute psychotic
symptoms.
2.2. Study Design. *e study was designed as a randomized
crossover trial with two groups (Figure 1). Group A started
with participation in the CS program for eight weeks, while
group B followed the usual care. After eight weeks, the
condition for both groups changed. For group A, assess-
ments took place before and after the intervention (pre-
intervention vs. postintervention) as well as six weeks after
the intervention had ﬁnished (follow up, FU). During the FU
period, group A received the usual care. For group B, as-
sessments took place before and after eight weeks of usual
care (pre- vs. post-usual care/preintervention), as well as
after the intervention (postintervention), and six weeks
thereafter (follow up, FU). *e group A phase between
postintervention and FU was not added to the control group
(CG), as no or limited washout eﬀects could be expected for
our nonpharmacological intervention. Assessments were
scheduled one week before and after the
intervention/waiting period, respectively. All assessments
and intervention sessions were conducted with patients in
the ON state.
*e allocation to group A or B was conducted by an
independent member of the research group who was not
involved in the study. Each group consisted of six patients.
After inclusion, participants were matched according to
their MMSE total score. *e pairs of matched individuals
were randomly allocated to either group A or B by picking
a note with the patient’s identiﬁcation code, which was
composed of two random letters and two random numbers,
from an urn.*e person whowas picked ﬁrst was assigned to
group A and the second one to group B. Each group was split
into groups of three to meet the group size requirement for
the CS program.
*e participants and facilitators for the CS program were
not blinded. Both outcome assessors were blinded at the
beginning of the data collection, but at the subsequent time
points of assessment, only one assessor was blinded to the
group allocation for organizational reasons. Nursing staﬀ
involved in external assessments were not blind to the group
allocations.
2.3. Intervention Program. *e intervention comprises
a modiﬁcation of the structured CS program “NEUROvitalis
senseful” [16], which was used in a study with patients with
dementia living in a nursing home [17], and is a further
development of the standardized cognitive training program
“NEUROvitalis” [18]. NEUROvitalis senseful is oﬀered to
small groups (3 to 5 persons) over a period of eight weeks,
twice per week for 60 minutes. For PDD patients’ suitability,
the exercises were adapted according to the typical cognitive
and psychomotor proﬁle of PD patients. *us, we added
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more cognitive exercises targeting executive and visual-
spatial functions, as well as ﬁne motor skills training
(Supplementary Table 1). For this study, the manual with
detailed description for every session was translated to
Dutch by native speakers with excellent knowledge of the
German language and expertise in clinical neuropsychology.
*e program was carried out in the PD care unit by Dutch
psychologists with a Bachelor’s degree who were trained by
one of the developers of the program (AKF).
2.4. Control Group (CG). *e CG received the usual PD unit
care including a variety of nonpharmacological in-
terventions such as sports, music, and arts. *ese activities
were open and voluntary for all residents throughout the
study.
2.5. Outcomes. Cognitive functioning was assessed with the
Dutch version of the CERAD test battery [19] (plus a word
ﬂuency test [20] and the Trail Making Test (TMT) [21],
which are included in the German version “CERAD Plus”
[22]). *e CERAD total score as an index for global cog-
nition (max. 111 points) was calculated according to Seo
et al. [23]. Additionally, we chose the Clock Drawing Test
[24] to test visuoconstructive and executive functions.
Neuropsychiatric symptoms were assessed with the
Neuropsychiatric Inventory (NPI) [25], and depression was
assessed with the Geriatric Depression Scale (GDS) [26] and
the Cornell Scale for Depression in Dementia (CSDD) [27].
ADLs were measured with the Barthel Index [28] and QoL
with the Dutch version of the EQ-5D-5L [29] as self- and
external ratings and the 37-item version of the QUALIDEM
[30] as a second external assessment. *e QUALIDEM total
score was calculated [31]. For a detailed description of the
(neuro-)psychological test battery, see Supplementary
Table 2.
*e neuropsychological examinations were adminis-
tered in a ﬁxed order by two Dutch psychologists with
a Master’s degree trained in neuropsychological testing. *e
external assessments were conducted as interviews with the
nursing staﬀ most involved in the patients’ care.
Further data, including demographics and clinical de-
tails, were collected from the residents’ ﬁles. *e levodopa
equivalent daily dose (LEDD) was calculated with the
Levodopa Equivalent Dose Calculator (http://www.
parkinsonsmeasurement.org/toolBox/levodopaEquivalent
Dose.htm). *e Charlson Comorbidity Index (CCI) was
calculated to predict the risk for death from comorbid
diseases [32]. PDD was diagnosed according to the Move-
ment Disorders Society (MDS) task force Level I guidelines
[33].
2.6. Statistical Analysis. SPSS 25 statistics software (IBM)
was used for data analyses. Only patients who completed
at least 11 sessions of the CS program were included in
analyses. No further techniques for dealing with missing
data (e.g., imputations) were used. As the number of
participants in the special setting was naturally limited
and this was a pilot study, no a priori sample size cal-
culation was performed. A post hoc power analysis was
calculated using G∗power 3.1 [34]. Analyses were per-
formed for the main outcomes of this study: global
cognition, neuropsychiatric symptoms, depression, ADLs,
and quality of life.
*e alpha level was set at 0.05 for all analyses. An ad-
justment of p values (0.05) using Bonferroni correction
within those outcomes which had several subscores
(i.e., depression and QoL) was applied. *e eﬀect size r is
reported indicating small eﬀects from r ≥ 0.1 to r < 0.3,
medium eﬀects from r ≥ 0.3 to r < 0.5, and large eﬀects from
r ≥ 0.5 [35]. Mean scores and standard deviations for the
baseline characteristics of groups A and B were shown. We
used t-tests for normally distributed data and the Mann–
Whitney U test for nonnormally distributed data, re-
spectively. Gender and Hoehn and Yahr (H&Y) stages are
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Figure 1: Study design.
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shown as frequencies and compared using the chi-square
statistics.
Due to the speciﬁc crossover design, the total number
of participants in the CS group increases (group A +
group B, n � 12). *e Mann–Whitney U test was used to
compare between-group CS eﬀects. For this analysis, the
score diﬀerences from postintervention to pre-
intervention and from post-usual care to pre-usual care
were calculated, respectively. *e Wilcoxon signed-rank
test was used for within-group diﬀerences from post- to
preintervention (short-term eﬀects) and from FU to
preintervention (long-term eﬀects) for CS, as well as from
post-usual care to pre-usual care (short-term eﬀects) for
the CG. Due to the crossover design, no long-term eﬀects
analysis could be performed for the CG, as there was no
FU in that group.
3. Results
Figure 2 illustrates the sample size in this study. All 21
residents of the PD care unit were screened for eligibility,
12 of which could be included in the study. Two subjects
(one person per group) dropped out at the FU assessment
(dropout rate: 16.7%). *e residents attended between 11
and 16 CS sessions (participation score: 92.7%). *e
nursing staﬀ was very interested in the study process
and supported its organization. *e impression of the
trainer was that the residents were also pleased to par-
ticipate, and several individuals mentioned that they
enjoyed the CS sessions. During the study process, all
subjects (except for one resident) participated in activities
provided by the institution such as arts or music (Sup-
plementary Table 3).
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Figure 2: Flowchart of the participants recruited for this study.
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At baseline, all patients were classiﬁed as having PDD
according to the MDS criteria [33], except for the criteria of
absence of major depression (GDS ≥ 5 points), which was
reached in 10 of 12 patients. Groups A and B were com-
parable with regard to all baseline characteristics (Table 1).
No adverse eﬀects occurred in relation to CS partici-
pation. All outcomes for both groups with between- and
within-group statistics are presented in Table 2 (data were
largely complete).
3.1. Between-Group Eﬀects. *e between-group analysis
revealed a group diﬀerence favoring CS which just failed to
reach statistical signiﬁcance for the CERAD total score
(p � 0.067; r � 0.43) with a moderate eﬀect size, and also
a statistical trend for the NPI total score (p � 0.075; r � 0.42),
again with a moderate eﬀect size. *e post hoc power
analysis for the between-group eﬀects demonstrated a sta-
tistical power of 6.6% for small eﬀects, 21.1% for moderate
eﬀects, and 56.1% for large eﬀects.
3.2. Within-Group Eﬀects. *e within-group analysis
showed a positive trend, which just failed to reach statistical
signiﬁcance but showed a strong eﬀect size for the CERAD
total score (p � 0.060; r � 0.70) demonstrating an im-
provement of the CS group (n � 12) from pre- to post-
intervention. Preintervention to FU score comparisons
revealed an improvement for the GDS (p � 0.072; r � 0.61),
which again just failed to reach statistical signiﬁcance and
showed a large eﬀect size. A signiﬁcant deterioration was
shown for the Barthel index (p � 0.014; r � 0.71).
*e post hoc power analysis for the within-group CS
eﬀects demonstrated a statistical power of 9.5% for small
eﬀects, 48.9% for moderate eﬀects, and 94.2% for large
eﬀects.
*e comparison of the pre- and post-usual care as-
sessment of the CG revealed no signiﬁcant results. Figures 3
and 4 illustrate the changes in the CERAD total score and the
GDS for the CS and the CG for all assessment points. *e
descriptive data of the cognitive subtests and the QUAL-
IDEM subscores are presented in Supplementary Table 4.
4. Discussion
*is randomized crossover pilot study examined short- and
long-term eﬀects of an eight-week CS program for long-term
care residents with PDD.
Although our data must be regarded as preliminary due
to the small sample size, it shows that CS for PDD patients
might be an eﬀective therapy option. First of all, our
ﬁndings indicate that CS is a safe therapy option for
patients with PDD and has possible positive short-term
eﬀects on cognition and neuropsychiatric symptoms for
residents with PDD in long-term care. *ese beneﬁts were
demonstrated with between- and within-group analyses,
with moderate to strong eﬀect sizes for all eﬀects. Fur-
thermore, preliminary long-term CS beneﬁts were found
at the six-week FU for depressive symptoms, again with
a strong eﬀect size. Finally, a signiﬁcant deterioration was
Table 1: Baseline sociodemographic and clinical characteristics of the study sample.
Group A (n � 6) Group B (n � 6) p value
Age (years) 76.67 ± 5.58 76.50 ± 8.94 0.970
Gender (male/female) 5/1 5/1 1.000
Years of education 10.17 ± 1.60 9.50 ± 0.55 0.445
Family status 0.392
Unmarried 0 1
Married 3 1
Divorced 0 1
Widowed 3 3
Inpatient (months) 16.50 ± 14.95 10.33 ± 5.50 0.394
Hoehn & Yahr stage 0.255
1–1.5 0 0
2–2.5 2 1
3 0 2
4 2 2
5 2 1
Months since PD diagnosis 72.00 ± 37.18 74.00 ± 48.84 0.938
Months since dementia diagnosis 26.17 ± 28.20 27.67 ± 12.66 0.908
LEDD 290.17 ± 236.60 239.67 ± 228.06 0.714
CCI 3.50 ± 3.78 2.33 ± 1.03 0.937
Number of antidementiva 0.83 ± 0.98 1.00 ± 0.63 0.699
Number of antidepressiva 0.83 ± 1.17 0.42 ± 0.66 0.699
Number of other medications 11.11 ± 3.27 10.42 ± 2.33 0.699
MMSE (max. 30 points) 17.50 ± 5.75 18.17 ± 5.35 0.839
CERAD total score (max. 111 points) 39.17 ± 9.37 38.50 ± 13.78 0.924
GDS (max. 15 points) 6.00 ± 2.00 8.67 ± 4.46 0.394
Values are presented as the mean ± standard deviation or frequency. Abbreviations: LEDD, levodopa equivalent daily dose; CCI, Charlson Comorbidity
Index; MMSE, Mini-Mental State Examination; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; GDS, Geriatric Depression Scale.
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observed from baseline to FU in ADL performance of the
CS group.
Despite the small sample size, this pilot trial was able to
identify potential beneﬁcial eﬀects on cognitive and non-
cognitive parameters, which are consistent with CS meta-
analyses in non-PD dementia patients showing positive
eﬀects on global cognition [10–12]. Additionally, we revealed
a decrease in neuropsychiatric symptoms and depression,
corroborating the results of Folkerts et al. [12] who found CS
beneﬁts for patients with dementia living in long-term care.
Nevertheless, another meta-analysis did not ﬁnd such an
eﬀect [10]. However, a positive eﬀect on QoL, which was
demonstrated, e.g., in the Cochrane review by Woods et al.
[10], could not be revealed in this study. Future studies will
have to elucidate whether CS has the potential to improve
the QoL in PDD. One possible explanation for the lack of
QoL beneﬁts could be that QoL questionnaires were used
that were not sensitive for this speciﬁc patient group. *us,
the development and use of specially designed QoL ques-
tionnaires for PDD patients is an urgent purpose for future
studies. Also, further trials with larger PDD patient sample
sizes are needed to conﬁrm the potential of CS in this group.
Notably, our data show a signiﬁcant deterioration of
ADL in the CS group from preintervention to FU. As PDD is
a progressive neurodegenerative disease, and the impact on
daily functioning is its key characteristic, this decline can
most probably be ascribed to the progress of the disease.
However, in the light of this decline, the beneﬁts of CS
appear to be even more remarkable. Unfortunately, as an FU
assessment for the CG is lacking, no between-group analysis
was possible. *erefore, potentially diﬀerent rates of decline
in ADL will need to be the subject of future research.
4.1. Feasibility. *e intervention integrated well into the
daily routine of this specialized PD care unit, despite the fact
that the residents’ weekly schedule included further activi-
ties. *is is veriﬁed by the high participation score≥ 94%.
We, therefore, conclude that the CS program is feasible for
PDD patients. Furthermore, participants reported that they
enjoyed the CS sessions. *e nursing team was interested in
the study, helped with organizing the assessments, provided
information about each patient within the external assess-
ments, and arranged the CS sessions. *e CS materials
remained in the institution after the ﬁnal assessment, and the
program is still provided to the residents.
4.2. Limitations and Strengths of the Study. Some limitations
need to be considered when interpreting our ﬁndings. First,
the power of our study is limited due to the small sample
size. As we used the unique possibility to study CS eﬀects in
a specialized care unit for PDD patients, no a priori sample
size estimation was possible. However, it should be noted
that our post hoc power analyses indicated that the power for
the within-group eﬀects of the CS group was satisfactory at
94% for large eﬀects. Furthermore, it seems remarkable that
despite the small sample size, signiﬁcant clear trends with
moderate to large eﬀect sizes were found.
*e crossover design, which was used to enlarge our
sample size, may be associated with some critical aspects,
especially in a study of the eﬀects of a nonpharmacological
intervention, where no or limited washout eﬀects could be
expected. For example, no CG was available for analyzing
between-group diﬀerences of the long-term eﬀects. Fur-
thermore, the patients had diﬀerent numbers of measurement
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Figure 3: Median change of the CERAD total score (max. 111
points; higher scores indicating better performance) of the ex-
perimental (EG) and control group (CG) from pre-
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follow-up assessment.
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Figure 4: Median change of the Geriatric Depression Scale (GDS;
max. 15 points; lower scores indicating less depressive symptoms)
of the experimental (EG) and control group (CG) from pre-
intervention/pre-usual care to postintervention/post-usual care to
follow-up assessment.
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time points (three vs. four measurements). As PDD is
a progressive disease, a possible deterioration in group B from
pre-usual care to post-usual care assessment needs to be
considered. Finally, one of the two assessors was not blinded
to group allocation. Full blinding should be achieved in future
studies.
As indicated, participants reported that they enjoyed
participation in the CS program. However, a limitation is
that, we did not systematically collect data on the important
patient-related outcome. *erefore, future studies should
include measures of the individuals’ motivation and fun
while participating in a CS program. Possible approaches
may include the use of training diaries and speciﬁc ques-
tionnaires as well as short qualitative interviews at the end of
the CS program involving both participants and
relatives/nursing staﬀ for self- and external ratings.
A particular strength of the study is that it is the ﬁrst to
show preliminary data for the beneﬁcial eﬀects of CS in PDD
patients. *e consideration of the CONSORT guidelines for
study reporting is a further strength. Finally, we provide FU
data to investigate possible long-term eﬀects, which has been
lacking in many CS studies [10].
5. Conclusions
In conclusion, CS seems to be a promising and safe non-
pharmacological intervention to enhance cognitive and
noncognitive symptoms in PDD patients in long-term care.
Further research with larger sample sizes and longer FU
periods are of high importance to conﬁrm and specify the
eﬀects of CS for out- and inpatients with PDD. *e best-
suited frequency and duration of CS sessions should be
identiﬁed. Predictor analyses could help to identify factors
inﬂuencing CS beneﬁts. Finally, health economic evaluations
will be necessary.
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